NCT07061938View on ClinicalTrials.gov

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

January 20, 2027

Study Completion Date

June 20, 2027

Conditions
IgG4 Related Disease
Interventions
DRUG

ACE1831

ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.

DRUG

Lymphodepleting chemotherapy

Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy cyclophosphamide ahead of ACE1831 administration.

Trial Locations (1)

30322

Emory University, Atlanta

Sponsors
All Listed Sponsors
lead

Acepodia Biotech, Inc.

INDUSTRY

NCT07061938 - Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease | Biotech Hunter | Biotech Hunter